ストックスクリーナーアプリを入手
8.31
1.07%
-0.09
アフターアワーズ：
8.31
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN
ORIC Pharmaceuticals (ORIC) Gains on Buy Rating from Stifel Amid Positive Trial Outlook - GuruFocus
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) - The Globe and Mail
Buy Rating and $14 Target Set for Oric Pharmaceuticals (ORIC) - GuruFocus
Stifel initiates Oric Pharmaceuticals stock with buy rating By Investing.com - Investing.com Nigeria
Stifel initiates Oric Pharmaceuticals stock with buy rating - Investing.com
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
ORIC: Phase III prostate cancer trial set to start, with strong safety and efficacy data and robust cash runway - TradingView
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
ORIC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Oric Pharmaceuticals stock edges up 1.60% as company executives join Goldman Sachs healthcare event, oricpharma - Traders Union
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth - Streetwise Reports
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals stock falls 6.48% amid bearish momentum as Oric Pharmaceuticals honors cancer survivors - Traders Union
Oric Pharmaceuticals (ORIC) Sheds 6.5% as Shares Test Key Support LevelsUp Down Volume - newsline.com
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
ORIC Pharmaceuticals grants inducement equity to new hires - scanx.trade
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new ORIC hires receive stock options and RSU awards - Stock Titan
Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15 - Moomoo
Oric Pharmaceuticals stock under sustained selling pressure, trades near new support zone - Traders Union
This ORIC Pharmaceuticals Insider Increased Their Holding In The Last Year - Moomoo
ORIC Pharmaceuticals (ORIC) Stock Analysis Report | Financials & Insights - Benzinga España
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Oncology company ORIC plans June talks at Jefferies, Goldman events - Stock Titan
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC Stock Chart | ORIC PHARMACEUTICALS INC (NASDAQ:ORIC) - ChartMill
Trading Systems Reacting to (ORIC) Volatility - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Q1 2026 Earnings: Narrower-Than-Expected Loss, Pipeline Progress Keeps Focus on Key MilestonesEPS Guidance Update - newsline.com
ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches - Bez Kabli
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
User - The Chronicle-Journal
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed - Stock Titan
Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update - Stock Titan
Point72-affiliated filers report 0% ownership in ORIC (ORIC) amendment - Stock Titan
T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported - Stock Titan
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy By Investing.com - Investing.com Canada
Goldman Sachs Upgrades Oric Pharmaceuticals (ORIC) with $15 Pric - GuruFocus
Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript - GuruFocus
Oric Pharmaceuticals faces securities fraud probe after prostate cancer drug update causes 41% stock drop - Pluang
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
Pfizer (NYSE: PFE) discloses 3.3% holding in ORIC Pharmaceuticals - Stock Titan
Number of shareholders of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
ORIC: Oric PharmaceuticalsInteractive Chart - Zacks Investment Research
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):